Authors

Latest:

Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer

Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.

Abhirami Vivekanandarajah, MD

Latest:

Dr Vivekanandarajah on Identifying HER2-Mutated NSCLC in the Community Setting

Abhirami Vivekanandarajah, MD, shares how she tests and treats patients with HER2-mutated non–small cell lung cancer in the community setting.

Allen Mo, MD, PhD

Latest:

28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Jeff White

Latest:

Camidge and White on Crucial Aspects of Patient-Focused Oncology Communication

Camidge and White discuss the intersections between White’s head and neck cancer diagnosis and radiation oncology communications career.

Henry S. Park, MD, MPH

Latest:

Dr Park on the Role of Radiation Therapy in NSCLC

Henry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.

Doris M. Ponce, MD

Latest:

Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Adam Kittai, MD

Adam Kittai, MD, is an associate professor of medicine (hematology and medical oncology), the assistant director of Lymphoma Clinical Research and the CLL Clinical Research Leader at Mount Sinai

Latest:

Richter Transformation in the Era of Targeted Therapies

Adam Kittai, MD, discusses Richter transformation in the era of targeted therapies.

Deepu Madduri, MD, Mount Sinai Hospital

Latest:

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

George Lau, MD, FRCP, FAASLD

Latest:

Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCC

George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center

Latest:

Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

David O’Malley, MD

Latest:

Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC

Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.

Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center

Latest:

Closing Perspectives on R/R AML Treatment Advances

Panelists discuss future perspectives on the role of menin inhibitors in the treatment of acute lymphoblastic leukemia (AML), exploring potential advancements and clinical implications.

Leo Rasche, MD

Latest:

Dr Rasche on BCMA and GPRC5D Loss After Bispecific Antibody Therapy in Multiple Myeloma

Leo Rasche, MD, discusses BCMA and GPRC5D loss after bispecific antibody therapy in multiple myeloma.

Byoung Chul Cho, MD, PhD

Latest:

Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Muthu Veeraputhiran, MD

Latest:

The Evolving Treatment Landscape in Paroxysmal Nocturnal Hemoglobinuria

The treatment landscape for PNH is rapidly evolving, and clinicians have more effective and convenient treatment options for patients that have helped control the disease and improve survival. T

Larry Hanover

Latest:

Clinical Trial Diversity Efforts Gain Steam

Nearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.

Caroline Nebhan, MD, PhD

Latest:

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Nujsaubnusi C. Vue, MD

Latest:

Reflections of an Inaugural Gynecologic Oncology Fellow

Nujsaubnusi Vue, MD, shares reflections on the challenges, successes, and failures that she's encountered thus far as an inaugural fellow.

Daniel Sherbenou, MD, PhD

Latest:

Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple Myeloma

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Jared Kaltwasser

Latest:

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

Driven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.